Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22929 | 0.87 | — | — | |
| SCHEMBL6578876 | 0.87 | POLB (0.46) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL21538 | 0.80 | ESR2 (0.42) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL43455 | 0.80 | ESR2 (0.47) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL5543159 | 0.78 | CYP11B2 (0.42) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL22833 | 0.78 | CYP11B2 (0.42) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL2911926 | 0.78 | CYP11B2 (0.42) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL10355051 | 0.78 | SLC18A3 (0.54) | SLC18A3SIGMAR1 | |
| SCHEMBL676555 | 0.78 | CYP11B2 (0.42) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL1089522 | 0.76 | ESR2 (0.59) | POLBESR2ESR1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180112131-A1 | LIQUID CRYSTAL MEDIUM, OPTICAL DEVICE AND LIQUID CRYSTAL COMPOUND | JNC CORPORATION (JP) | 2018-04-26 | — | — | US | claimed |
| US-20160280996-A1 | ALKENYL DIOXANE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-09-29 | — | — | US | claimed |
| US-8419972-B2 | Polymerizable liquid crystal composition | JNC CORPORATION (JP) | 2013-04-16 | — | — | US | claimed |
| EP-2351808-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2011-08-03 | — | — | EP | claimed |
| WO-1999029670-A2 | AMINOCARBONYLTETRALIN AND DIHYDRONAPHTALENE DERIVATES AS THROMBIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-06-17 | — | — | WO | claimed |
| EP-0799202-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1997-10-08 | — | — | EP | claimed |
| US-5211877-A | Crosslinked resins | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1993-05-18 | — | — | US | claimed |
| EP-0250961-B1 | CHIRAL ESTERS OF ALPHA-SUBSTITUTED PHENYLALKYLIC ACIDS AND MESOGENEOUS HYDROXYL COMPOUNDS, AND THEIR USE AS DOPANTS IN LIQUID-CRYSTAL PHASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-22 | — | — | EP | claimed |
| CN-111253953-B | Liquid crystal composition and element for phase control of electromagnetic wave signal | 捷恩智株式会社 | 2024-02-23 | — | — | CN | disclosed |
| US-20200239775-A1 | TETRACYCLIC LIQUID CRYSTAL COMPOUND HAVING DIATOMIC BONDING GROUP AND 2,3-DIFLUOROPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-07-30 | — | — | US | disclosed |
| US-10633589-B2 | Liquid crystal medium, optical device and liquid crystal compound | JNC CORPORATION (JP) | 2020-04-28 | — | — | US | disclosed |
| CN-107109226-B | Liquid crystal composition and liquid crystal display element | 捷恩智株式会社 | 2020-01-07 | — | — | CN | disclosed |
| EP-3103856-B1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2019-09-18 | — | — | EP | disclosed |
| EP-2698414-B1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2019-03-13 | — | — | EP | disclosed |
| EP-1160251-A2 | Liquid crystalline compounds having a silane diyl group, liquid crystal compositions comprising the same and liquid crystal display devices | CHISSO CORPORATION (JP) | 2001-12-05 | — | — | EP | disclosed |
| WO-1999029670-A2 | AMINOCARBONYLTETRALIN AND DIHYDRONAPHTALENE DERIVATES AS THROMBIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-06-17 | — | — | WO | disclosed |
| EP-0799202-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1997-10-08 | — | — | EP | disclosed |
| EP-0250961-B1 | CHIRAL ESTERS OF ALPHA-SUBSTITUTED PHENYLALKYLIC ACIDS AND MESOGENEOUS HYDROXYL COMPOUNDS, AND THEIR USE AS DOPANTS IN LIQUID-CRYSTAL PHASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-22 | — | — | EP | disclosed |
| US-4678283-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-07-07 | — | — | US | disclosed |
| EP-0144013-A2 | Thienothiophene derivatives | MERCK PATENT GmbH (DE) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280996-A1 | ALKENYL DIOXANE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, HAX1 | POLB 3891/4885ESR2 2418/4885ESR1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.